Literature DB >> 32762171

[Comparative analysis of structural characteristics and epitopes in S proteins between SARS-CoV-2 and SARS-CoV].

Yongzhi Lun1, Ben Liu1, Wen Dong1, Jie Sun1, Linghong Pan1.   

Abstract

OBJECTIVE: To provide data support for the study of pathogenic mechanism of SARS-CoV-2 at the molecular level, and provide suitable candidate targets for vaccine, antibody and drug research and development through comparative analysis for structural characteristics and epitopes of S protein of SARS-CoV-2 and SARS-CoV.
METHODS: Based on the reference sequences of S protein, physical and chemical properties, hydrophobicity, signal peptide, transmembrane region, domain, secondary structure, tertiary structure analysis and antigenic epitopes prediction were carried out. Meanwhile, the tissue expression, related pathways and reactome pathways of angiotensis Ⅰ converting enzyme 2 (ACE2) and C-type lectin domain family 4 member M (CLEC4M) receptors were analyzed.
RESULTS: The amino acid sequence of S protein of SARS-CoV-2 and SARS-CoV has a 75.80% consistency. The structural characteristics of the two coronaviruses are highly consistent, but the secondary structure and tertiary structure of SARS-CoV-2 is not as obvious as SARS-CoV. ACE2 and CLEC4M are expressed in alimentary system, heart, kidney, lung and placenta. The main related the pathways of renin-angiotensin system, protein digestion and absorption pathway, and the reactome pathways of metabolism of angiotensinogen to angiotensins, GPCR ligand binding, are related to typical symptoms of coronavirus disease 2019 induced by SARS-CoV-2. Three pairs of highly or completely homologous epitopes of S protein were obtained. The 600-605, 695-703 and 888-896 amino acid residues in SARS-CoV-2 were highly homologous with 586-591, 677-685 and 870-878 amino acid residues in SARS-CoV, respectively.
CONCLUSIONS: The similarity of S protein of SARS-CoV-2 and SARS-CoV determines that they have similar infection patterns and clinical manifestations. The candidate epitopes with high reliability can provide reference for virus diagnosis and vaccine development.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32762171      PMCID: PMC8800722          DOI: 10.3785/j.issn.1008-9292.2020.05.01

Source DB:  PubMed          Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban        ISSN: 1008-9292


  26 in total

1.  SignalP 4.0: discriminating signal peptides from transmembrane regions.

Authors:  Thomas Nordahl Petersen; Søren Brunak; Gunnar von Heijne; Henrik Nielsen
Journal:  Nat Methods       Date:  2011-09-29       Impact factor: 28.547

2.  Improved methods for predicting peptide binding affinity to MHC class II molecules.

Authors:  Kamilla Kjaergaard Jensen; Massimo Andreatta; Paolo Marcatili; Søren Buus; Jason A Greenbaum; Zhen Yan; Alessandro Sette; Bjoern Peters; Morten Nielsen
Journal:  Immunology       Date:  2018-02-06       Impact factor: 7.397

3.  Clustal W and Clustal X version 2.0.

Authors:  M A Larkin; G Blackshields; N P Brown; R Chenna; P A McGettigan; H McWilliam; F Valentin; I M Wallace; A Wilm; R Lopez; J D Thompson; T J Gibson; D G Higgins
Journal:  Bioinformatics       Date:  2007-09-10       Impact factor: 6.937

Review 4.  Broadly neutralizing antibodies against influenza viruses.

Authors:  Nick S Laursen; Ian A Wilson
Journal:  Antiviral Res       Date:  2013-04-09       Impact factor: 5.970

5.  Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion.

Authors:  Alexandra C Walls; M Alejandra Tortorici; Joost Snijder; Xiaoli Xiong; Berend-Jan Bosch; Felix A Rey; David Veesler
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-03       Impact factor: 11.205

6.  Protease-mediated entry via the endosome of human coronavirus 229E.

Authors:  Miyuki Kawase; Kazuya Shirato; Shutoku Matsuyama; Fumihiro Taguchi
Journal:  J Virol       Date:  2008-10-29       Impact factor: 5.103

Review 7.  Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.

Authors:  Melissa M Coughlin; Bellur S Prabhakar
Journal:  Rev Med Virol       Date:  2011-09-08       Impact factor: 6.989

8.  InterPro in 2019: improving coverage, classification and access to protein sequence annotations.

Authors:  Alex L Mitchell; Teresa K Attwood; Patricia C Babbitt; Matthias Blum; Peer Bork; Alan Bridge; Shoshana D Brown; Hsin-Yu Chang; Sara El-Gebali; Matthew I Fraser; Julian Gough; David R Haft; Hongzhan Huang; Ivica Letunic; Rodrigo Lopez; Aurélien Luciani; Fabio Madeira; Aron Marchler-Bauer; Huaiyu Mi; Darren A Natale; Marco Necci; Gift Nuka; Christine Orengo; Arun P Pandurangan; Typhaine Paysan-Lafosse; Sebastien Pesseat; Simon C Potter; Matloob A Qureshi; Neil D Rawlings; Nicole Redaschi; Lorna J Richardson; Catherine Rivoire; Gustavo A Salazar; Amaia Sangrador-Vegas; Christian J A Sigrist; Ian Sillitoe; Granger G Sutton; Narmada Thanki; Paul D Thomas; Silvio C E Tosatto; Siew-Yit Yong; Robert D Finn
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

9.  Reconstitution of the receptor-binding motif of the SARS coronavirus.

Authors:  Natalia T Freund; Anna Roitburd-Berman; Jianhua Sui; Wayne A Marasco; Jonathan M Gershoni
Journal:  Protein Eng Des Sel       Date:  2015-10-20       Impact factor: 1.650

Review 10.  Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features.

Authors:  David S C Hui; Alimuddin Zumla
Journal:  Infect Dis Clin North Am       Date:  2019-12       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.